Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740225 | 0.88 | RAPGEF3 (0.39) | STING1RAPGEF3 | |
| SCHEMBL26882783 | 0.83 | LMNA (0.36) | — | |
| SCHEMBL26780258 | 0.78 | TDP1 (0.41) | — | |
| SCHEMBL706579 | 0.78 | TDP1 (0.41) | — | |
| SCHEMBL26882779 | 0.78 | ACHE (0.33) | ACHE | |
| SCHEMBL27065057 | 0.78 | ACHE (0.33) | ACHE | |
| SCHEMBL27056650 | 0.78 | ACHE (0.33) | ACHE | |
| SCHEMBL1798801 | 0.77 | PDE4A (0.45) | STING1ACHE | |
| SCHEMBL1798803 | 0.77 | PDE4A (0.45) | STING1ACHE | |
| SCHEMBL3285873 | 0.77 | PRMT5 (0.36) | RAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | disclosed |
| US-7125855-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | STING1 1026/4885RAPGEF3 3188/4885ACHE 1681/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | STING1 503/4885RAPGEF3 3460/4885ACHE 3600/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | STING1 233/4885RAPGEF3 2098/4885ACHE 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.